Epitope Mapping of Rhi o 1 and Generation of a Hypoallergenic Variant: A CANDIDATE MOLECULE FOR FUNGAL ALLERGY VACCINES

J Biol Chem. 2016 Aug 19;291(34):18016-29. doi: 10.1074/jbc.M116.732032. Epub 2016 Jun 28.

Abstract

Efficacy of allergen-specific immunotherapy is often severely impaired by detrimental IgE-mediated side effects of native allergen during vaccination. Here, we present the molecular determinants for IgE recognition of Rhi o 1 and eventually converting the allergen into a hypoallergenic immunogen to restrain health hazards during desensitization. Rhi o 1 is a respiratory fungal allergen. Despite having cross-reactivity with cockroach allergen, we observed that non-cross-reactive epitope predominantly determined IgE binding to Rhi o 1. Denaturation and refolding behavior of the allergen confirmed that its IgE reactivity was not essentially conformation-dependent. A combinatorial approach consisting of computational prediction and a peptide-based immunoassay identified two peptides ((44)TGEYLTQKYFNSQRNN and (311)GAEKNWAGQYVVDCNK) of Rhi o 1 that frequently reacted with IgE antibodies of sensitized patients. Interestingly, these peptides did not represent purely linear IgE epitopes but were presented in a conformational manner by forming a spatially clustered surface-exposed epitope conferring optimal IgE-binding capacity to the folded allergen. Site-directed alanine substitution identified four residues of the IgE epitope that were crucial for antibody binding. A multiple mutant (T49A/Y52A/K314A/W316A) showing 100-fold lower IgE binding and reduced allergenic activity was generated. The TYKW mutant retained T-cell epitopes, as evident from its lymphoproliferative capacity but down-regulated pro-allergic IL-5 secretion. The TYKW mutant induced enhanced focusing of blocking IgG antibodies specifically toward the IgE epitope of the allergen. Anti-TYKW mutant polyclonal IgG antibodies competitively inhibited binding of IgE antibodies to Rhi o 1 up to 70% and suppressed allergen-mediated histamine release by 10-fold. In conclusion, this is a simple yet rational strategy based on epitope mapping data to develop a genetically modified hypoallergenic variant showing protective antibody response for immunotherapeutic applications.

Keywords: allergen; asthma; epitope mapping; immunoglobulin E (IgE); immunotherapy; mold allergy; mutagenesis; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allergens* / chemistry
  • Allergens* / genetics
  • Allergens* / immunology
  • Animals
  • Cell Line
  • Epitope Mapping*
  • Epitopes, T-Lymphocyte* / chemistry
  • Epitopes, T-Lymphocyte* / genetics
  • Epitopes, T-Lymphocyte* / immunology
  • Female
  • Fungal Proteins* / chemistry
  • Fungal Proteins* / genetics
  • Fungal Proteins* / immunology
  • Humans
  • Immunoglobulin E / chemistry
  • Immunoglobulin E / immunology
  • Immunoglobulin G / chemistry
  • Immunoglobulin G / immunology
  • Male
  • Rhizopus* / chemistry
  • Rhizopus* / genetics
  • Rhizopus* / immunology
  • Vaccines* / chemistry
  • Vaccines* / genetics
  • Vaccines* / immunology

Substances

  • Allergens
  • Epitopes, T-Lymphocyte
  • Fungal Proteins
  • Immunoglobulin G
  • Vaccines
  • Immunoglobulin E